Identification of the need for pharmaceutical care within the prevention strategy of CHD: a study in acute MI patients

Focal points □ Aspirin use in primary prevention candidates overall was only 11% □ Of those patients with a CHD risk of 30% or more and a total cholesterol of mmol/L or more, only 10% were receiving a statin □ Statin use in secondary prevention was only 47% of candidates □ The use of aspirin, s-blockers and angiotensin converting enzyme inhibitors in secondary prevention was 65, 44 and 36%, respectively □ The gaps in provision of CHD prevention are highlighted when seen among those destined to suffer AMI; they call for pharmacists to be part of local initiatives to improve standards of CHD prevention